[A23-23] Dupilumab (eosinophilic oesophagitis) – Benefit assessment according to §35a Social Code Book V

Last updated 03.07.2023

Project no.:

Commission awarded on 30.03.2023 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:
Immune system and infections


Eosinophilic oesophagitis (EoE)

Result of dossier assessment:
  • Adults with EoE who are still candidates for treatment with budesonide because they have not yet received budesonide: added benefit not proven
  • Adults and adolescents with EoE, 12 years and older, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy: added benefit not proven

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.


Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form